Stage III Endometrial Cancer clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

First-line treatment for advanced or recurrent endometrial cancer

This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).

Trial for early uterine cancer with POLE mutation after surgery

This Phase 2 trial studies an added (adjuvant) treatment for early-stage uterine cancer that has a specific genetic change called POLE mutation and does not have a p53 abnormal pattern. The goal is to lower the risk of the cancer coming back after surgery.

Online program to ease fear of cancer returning

This study tests an online program designed to help women with advanced or certain types of breast or gynecologic cancer manage their fear of the disease progressing or returning. The program aims to reduce anxiety and improve quality of life.

Find targeted cancer treatments using genetic testing

This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.

New drug vs standard chemo for HER2-positive endometrial cancer

This trial compares a new targeted medicine (trastuzumab deruxtecan) against standard chemotherapy for women with a certain type of advanced endometrial cancer that has high levels of HER2 protein. It's for people whose cancer is newly diagnosed and has spread to nearby tissues but not to distant organs.

Lymph node surgery study for certain early endometrial cancers

This trial studies whether adding lymph node removal (lymphadenectomy) during surgery helps people with certain early-stage endometrial cancer. It focuses on patients who do not have visibly enlarged lymph nodes and who can safely have the operation.

Predicting response to hormone treatment in endometrial cancer

This study looks at whether biopsy test results can help predict how well hormone therapy will work for advanced or recurrent endometrial cancer. It may help doctors choose the most effective hormonal treatment sooner.

Testing best added chemo and radiation after stage III uterine cancer

This study compares different ways of giving radiation and chemotherapy after surgery for stage III endometrial (uterine) cancer. It aims to find which approach works best to reduce cancer risk and improve outcomes.

Tracking surgery choices for lymph node spread in endometrial cancer

This is an observational study that follows people with endometrial cancer who have had surgery to check and remove pelvic (and sometimes paraaortic) lymph nodes. It looks at how different surgical approaches and any added treatment affect local control (keeping cancer from coming back in the pelvis/nearby areas).

Prehab program for gynecologic cancer before treatment

This trial tests whether a structured “prehab” program (before major cancer treatment) can improve how well people tolerate therapy and recover. It focuses on people with certain ovarian or early endometrial cancers who need additional treatment planning, including timing of surgery or chemotherapy.

Testing uterine fluid to help detect ovarian cancer

This study checks whether a sample of fluid from the uterus (uterine lavage) can help detect ovarian or fallopian tube cancer. You may join if you are having certain gynecologic surgeries or, in a smaller group, you have a BRCA1/2 mutation.

Sentinel node biopsy versus full node removal in early uterine cancer

This study compares two ways to check lymph nodes during surgery for early-stage endometrial (uterine) cancer: sentinel node biopsy versus removing more lymph nodes. It may help find whether the less extensive approach can stage the cancer accurately with fewer side effects.

ctDNA test for guiding endometrial cancer treatment decisions

This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.

Exercise during chemo to prevent weakness from low movement

This study tests whether a structured exercise program during chemotherapy can help prevent physical decline (“immobility,” like getting weaker or moving less) in people with certain ovarian or endometrial cancers. If you’re eligible, you may be guided to exercise while receiving standard chemo, and you’ll have blood tests to track changes.

Study drug IACS-6274 tested for advanced solid tumors

This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.

Test DNA blood and tissue markers to detect gynecologic cancers

This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.

Tumor treating device plus targeted or immune drugs for advanced cancers

This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.

Registry for advanced ovarian or endometrial cancer patients

This registry collects information from people with advanced ovarian or endometrial cancer to better understand care and outcomes. It may help researchers and doctors learn which treatments work best for different patients.

Short-course radiation plus chemotherapy for endometrial cancer

This early-phase study tests whether giving a short course of radiation together with chemotherapy can help treat endometrial cancer after surgery. It aims to find a treatment plan that is effective while keeping side effects manageable.

Nivolumab for resected mismatch-repair deficient endometrial cancer

This trial studies nivolumab (an immune therapy that helps your body recognize cancer) after surgery for endometrial cancer that has mismatch-repair deficiency (MMR-d) or high microsatellite instability (MSI-H). It aims to lower the chance the cancer comes back by treating “leftover risk” after the tumor is removed.

Radiation after surgery for stage III uterine cancer

This trial studies a specific type of radiation treatment given after surgery for people with stage III endometrial (uterine lining) cancer. It’s meant to see how well this “shorter/targeted” radiation approach works to help control the cancer after hysterectomy and staging.

Looking for cancer mutations using a blood test

This study uses a blood test (liquid biopsy) to find genetic changes in advanced solid tumors. It may help doctors choose the right treatment and monitor how well it works over time.

Dostarlimab for early-stage MMR deficient endometrial cancer

This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.